Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients

Author(s):  
Sergio Vañó-Galván ◽  
Rodrigo Pirmez ◽  
Angela Hermosa-Gelbard ◽  
Óscar M. Moreno-Arrones ◽  
David Saceda-Corralo ◽  
...  
2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Juan Jimenez‐Cauhe ◽  
David Saceda‐Corralo ◽  
Rita Rodrigues‐Barata ◽  
Oscar M. Moreno‐Arrones ◽  
Daniel Ortega‐Quijano ◽  
...  

2021 ◽  
Vol 84 (1) ◽  
pp. 222-223
Author(s):  
Juan Jimenez-Cauhe ◽  
David Saceda-Corralo ◽  
Rita Rodrigues-Barata ◽  
Angela Hermosa-Gelbard ◽  
Oscar M. Moreno-Arrones ◽  
...  
Keyword(s):  
Low Dose ◽  

2021 ◽  
Vol 1 ◽  
pp. 38
Author(s):  
Sajin Alexander ◽  
Venkataram Mysore ◽  
Ashwini L. Hirevenkangoudar

Low-dose oral minoxidil (OM) has increasingly been used by many doctors around the world as a treatment option for hair loss. Sufficient data regarding its effect and side effect profile are lacking. An online search was done on PUBMED and GOOGLE SCHOLAR for articles that used OM as a treatment option for hair loss. Doses ranging from 0.25 to 5 mg have been used for treatment in various studies. Good compliance and tolerability have been noticed with low-dose OM therapy. Adverse effects are few and are mild with hypertrichosis being the most common adverse effect in a majority of the studies, the risk of which increases with an increase in dosage of the drug.


2020 ◽  
Vol 6 (3) ◽  
pp. 175-176 ◽  
Author(s):  
Rita Rodrigues-Barata ◽  
Oscar M. Moreno-Arrones ◽  
David Saceda-Corralo ◽  
Juan Jiménez-Cauhé ◽  
Daniel Ortega-Quijano ◽  
...  

2001 ◽  
Vol 1 (3) ◽  
pp. 123-131 ◽  
Author(s):  
J. Michael Maloney ◽  
Deborah I. Arbit ◽  
Mary Flack ◽  
Constance McLaughlin-Miley ◽  
Cynthia Sevilla ◽  
...  

2001 ◽  
Vol 21 (02) ◽  
pp. 77-81 ◽  
Author(s):  
G. Finazzi

SummaryThrombotic events are a major clinical problem for patients with antiphospholipid antibodies (APA). However, current recommendations for their prevention and treatment are still based on retrospective studies. Data from large scale, prospective clinical trials are required to ultimately identify the optimal management of these patients. To date, at least four randomized studies are underway. The WAPS and PAPRE clinical trials are aimed to establish the correct duration and intensity of oral anticoagulation in APA patients with major arterial or venous thrombosis. The WARSS-APASS is a collaborative study to evaluate the efficacy and safety of aspirin or low-dose oral anticoagulants in preventing the recurrence of ischemic stroke. The recently announced UK Trial compares low-dose aspirin with or without low-intensity anticoagulation for the primary prevention of vascular events in APA-positive patients with SLE or adverse pregnancy history, but still thrombosis-free. It is hoped that the results of these trials will be available soon since clinicians urgently need more powerful data to treat their patients with the APA syndrome.


1992 ◽  
Vol 68 (02) ◽  
pp. 160-164 ◽  
Author(s):  
P J Braun ◽  
K M Szewczyk

SummaryPlasma levels of total prothrombin and fully-carboxylated (native) prothrombin were compared with results of prothrombin time (PT) assays for patients undergoing oral anticoagulant therapy. Mean concentrations of total and native prothrombin in non-anticoagulated patients were 119 ± 13 µg/ml and 118 ± 22 µg/ml, respectively. In anticoagulated patients, INR values ranged as high as 9, and levels of total prothrombin and native prothrombin decreased with increasing INR to minimum values of 40 µg/ml and 5 µg/ml, respectively. Des-carboxy-prothrombin increased with INR, to a maximum of 60 µg/ml. The strongest correlation was observed between native prothrombin and the reciprocal of the INR (1/INR) (r = 0.89, slope = 122 µg/ml, n = 200). These results indicated that native prothrombin varied over a wider range and was more closely related to INR values than either total or des-carboxy-prothrombin. Levels of native prothrombin were decreased 2-fold from normal levels at INR = 2, indicating that the native prothrombin antigen assay may be a sensitive method for monitoring low-dose oral anticoagulant therapy. The inverse relationship between concentration of native prothrombin and INR may help in identification of appropriate therapeutic ranges for oral anticoagulant therapy.


Sign in / Sign up

Export Citation Format

Share Document